NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/08/2026
Voltar para busca
Dado oficial do USPTO
IKSUDA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
IKSUDA
ST13
US500000079240120Classe
1, 5, 16, 42
Pedido
79240120
Registro
5766418
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
06/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 16, 42
Data de depósito
17/05/2018
Data de registro
04/06/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/10/2025
Última transação
06/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
MICHOS, JOHN E
Localização atual
Historical data usage
Titulares e representantes
Titulares
IKSUDA THERAPEUTICS LIMITED
Representantes
William S. Fultz Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 16Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; chemical preparations for scientific and industrial processesvinyl pyridine-based linkersvinyl pyridine derivativesdifluorosialic acid; enzymes for industrial use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs
Classe 5
Pharmaceuticals for the treatment of cancer; pharmaceuticals and medical preparations for the treatment of inflammatory diseases; vaccines for the treatment of cancer; vaccines for the treatment of gene and cell therapy; vaccines for the treatment of inflammatory diseases; pharmaceutical and medical preparations for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical products for the prevention and treatment of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals for the treatment of inflammatory diseases; hormones and analogues for medical purposes; biopharmaceutical and pharmaceutical gene and cell therapy productstherapeutic pharmaceuticals for the treatment of cancertumorsinfectiousoncologicalautoimmuneimmune system diseases and disorders
Classe 16
Paper; cardboard; printed matterpaper signsbooksmanualsbusiness cardsnewslettersinformational cardspostersbrochuresletterscertificates in the field of biotherapeutics; bookbinding material; photographs; stationery; printed instructionaleducationalteaching materials in the field of medicine; publicationsbookshand-outsworkbookspostersresearch articles in the fields of sciencemedicine and biotherapeutics; publications for the medical professionmagazinesnewslettersresearch articles in the field of medicine
Classe 42
Scientific and technological servicesscientific researchdesignanalysis and testing in the field of biotherapeutics for treating cancer; medical and pharmaceutical research services; research and development of vaccines and medicines; industrial analysis and research servicessynthetic chemistrybioconjugationscientific analysis of antibody-drug conjugates and biotherapeutics; scientific research; pharmaceutical research; biological research; biotechnology testing servicessynthetic chemistryrecombinant protein productionbioconjugationtestinganalysisevaluation of antibody-drug conjugates and biotherapeutics to assure compliance with industry standards; medical research services in the field of cancer; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; conducting clinical trials for others; design of clinical trials for others in the field of vaccines and gene therapy; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; informationadvisory and consultancy services relating to the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
08/06/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
08/10/2025
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
08/10/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/10/2025
ES71
TEAS SECTION 71 RECEIVED
27/06/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/11/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/06/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/02/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/01/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/10/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/09/2019
FIMP
FINAL DISPOSITION PROCESSED
12/09/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/09/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
04/06/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/03/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/03/2019
PUBO
PUBLISHED FOR OPPOSITION
19/03/2019
GPNX
NOTIFICATION PROCESSED BY IB
16/03/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/02/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/02/2019
NPUB
NOTICE OF PUBLICATION
27/02/2019
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
13/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/02/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/02/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/02/2019
ALIE
ASSIGNED TO LIE
04/02/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/02/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/01/2019
RFNT
REFUSAL PROCESSED BY IB
13/10/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
24/09/2018
RFRR
REFUSAL PROCESSED BY MPU
24/09/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/09/2018
MAFR
APPLICATION FILING RECEIPT MAILED
18/09/2018
CNRT
NON-FINAL ACTION WRITTEN
17/09/2018
DOCK
ASSIGNED TO EXAMINER
13/09/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/09/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/09/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IKSUDA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.